EICIX
Price
$18.49
Change
+$0.05 (+0.27%)
Updated
Jun 2 closing price
Net Assets
366.65M
RMFCX
Price
$62.47
Change
+$0.39 (+0.63%)
Updated
Jun 2 closing price
Net Assets
114.65B
Interact to see
Advertisement

EICIX vs RMFCX

Header iconEICIX vs RMFCX Comparison
Open Charts EICIX vs RMFCXBanner chart's image
EICIX vs RMFCX Comparison Chart in %
View a ticker or compare two or three
VS
EICIX vs. RMFCX commentary
Jun 04, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EICIX is a Hold and RMFCX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 115B vs. EICIX (367M). EICIX pays higher dividends than RMFCX: EICIX (2.19) vs RMFCX (1.19). EICIX was incepted earlier than RMFCX: EICIX (15 years) vs RMFCX (24 years). EICIX (0.98) is less costly to investors than RMFCX (0.91). RMFCX (30.00) and EICIX (29.00) have comparable annual turnover. RMFCX has a lower initial minimum investment than EICIX: RMFCX (250) vs EICIX (10000). RMFCX annual gain was more profitable for investors over the last year : 10.10 vs. EICIX (4.67). RMFCX return over 5 years is better than : 33.85 vs. EICIX (19.22).
EICIXRMFCXEICIX / RMFCX
Total Expense Ratio0.960.91105%
Annual Report Gross Expense Ratio0.980.91108%
Fund Existence15 years24 years-
Gain YTD3.0175.84552%
Front LoadN/AN/A-
Min. Initial Investment100002504,000%
Min. Initial Investment IRAN/AN/A-
Net Assets367M115B0%
Annual Yield % from dividends2.191.19184%
Returns for 1 year4.6710.1046%
Returns for 3 years32.4534.6594%
Returns for 5 years19.2233.8557%
Returns for 10 years65.5091.4672%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HOVNP20.810.08
+0.36%
Hovnanian Enterprises
BLD407.07-5.12
-1.24%
TopBuild Corp
IMOS64.61-1.96
-2.94%
ChipMOS TECHNOLOGIES
FLNA1.44-0.05
-3.36%
Filana Therapeutics Inc
OVID2.40-0.16
-6.25%
Ovid Therapeutics